Literature DB >> 33491255

Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer.

Keywan Mortezaee1,2.   

Abstract

Cold tumors generally show low mutational burden and low infiltration of effector T cells. The pancreas, prostate, ovary, breast, and colon are placed into the category of cold tumors. In such tumors, effector T cells are either excluded from the tumor area or taken away from being in contact with tumor cells. The stromal reaction in the form of desmoplasia is important for the pathogenesis of tumors like the pancreas. Besides acting as a barrier for the penetration of drugs into the tumor area, the dense stroma presumably creates an immunosuppressive tumor microenvironment (TME), which accounts for low responses from tumor to immunotherapy. Cancer stem cells (CSCs) are an important part of the immunosuppressive complex within the TME. The presence of CSCs within the TME is related negatively to the activity of the antitumor immune system. Here, the question is how desmoplastic aggregates can influence the functionality of CSCs for promoting a cold pancreatic tumor immunity? This review is aimed at responding to this question, the disruption of which can be an effective strategy for improving responses from cold tumors to immunotherapy.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  CD8+ cytotoxic T lymphocyte; cancer stem cell; cancer-associated fibroblast; cold tumor; desmoplasia; extracellular matrix; immunotherapy; pancreatic cancer; transforming growth factor; tumor microenvironment

Mesh:

Year:  2021        PMID: 33491255     DOI: 10.1002/jbt.22708

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  15 in total

Review 1.  Key promoters of tumor hallmarks.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Int J Clin Oncol       Date:  2021-11-13       Impact factor: 3.402

Review 2.  Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated.

Authors:  Keywan Mortezaee; Jamal Majidpoor; Ebrahim Kharazinejad
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

Review 3.  Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Cell Oncol (Dordr)       Date:  2022-05-19       Impact factor: 7.051

Review 4.  Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.

Authors:  Tomas Koltai; Stephan Joel Reshkin; Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Khalid Omer Alfarouk; Rosa Angela Cardone
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

5.  CILP, a Putative Gene Associated With Immune Infiltration in Breast Cancer Brain Metastases.

Authors:  Xiaolin Sun; Ning Yang; Xingguo Zhou; Honghai Dai; Qiang Li; Alei Feng; Gongwen Xu; Yingchao Liu; Linzong Xu; Zhanyu Zhang; Zhe Yang; Xiaomei Li
Journal:  Front Genet       Date:  2022-05-30       Impact factor: 4.772

Review 6.  Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells.

Authors:  Susmita Barman; Iram Fatima; Amar B Singh; Punita Dhawan
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 7.  (Im)maturity in Tumor Ecosystem.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

8.  Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma.

Authors:  Fei-Ting Hsu; Chang Liang Tsai; I-Tsang Chiang; Keng-Hsueh Lan; Po-Fu Yueh; Wen-Yi Liang; Chi-Shuo Lin; Yee Chao; Keng-Li Lan
Journal:  J Cell Mol Med       Date:  2022-02-17       Impact factor: 5.310

Review 9.  CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

Review 10.  The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma.

Authors:  Jorge Melendez-Zajgla; Vilma Maldonado
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.